| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.1 |
| Profit before tax | -53.0 | -35.5 |
| Net income | -53.1 | -35.5 |
| EPS (diluted, $ a share) | $-1.10 | $-7.78 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ODTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Odyssey Therapeutics, Inc.: key numbers
- Share price
- $19.36Close, Nov 16
- Market cap
- $931M
- Shares outstanding
- 48.07MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Odyssey Therapeutics, Inc.
All →Odyssey Therapeutics Financial Results
Odyssey Therapeutics reported third quarter 2026 financial results, ending the period with $387 million in cash and equivalents. The company highlighted clinical progress for its RIPK2 inhibitor OD-001 in ulcerative colitis and the completion of IND-enabling studies for its SLC15A4 inhibitor OD-002.
- Term
- Q3 2026
“Over the past several months, we have made meaningful progress across our entire pipeline, highlighted by additional analyses from the Phase 2a induction period for OD-001 demonstrating that clinical efficacy is supported by concordant biomarker and transcriptomic findings, further reinforcing previously established clinical proof of concept in patients with ulcerative colitis.”
Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics
“We have also continued to advance the clinical development of OD-001 while completing IND-enabling studies for OD-002, our SLC15A4 inhibitor. Together with an enhanced executive leadership team and strong financial foundation, these achievements position us to execute on our clinical development strategy and drive continued progress throughout our portfolio.”
Gary D. Glick, Ph.D., founder and chief executive officer of Odyssey Therapeutics
Odyssey Therapeutics Clinical Trial Data
Odyssey Therapeutics announced positive Phase 2a results for its oral RIPK2 inhibitor, OD-001, in patients with moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a 27% clinical remission rate at the 20 mg BID dose at Week 12, showing significant correlation between clinical efficacy and inflammatory biomarkers.